Gene signature for immune therapies in cancer
An immune response subtype of cancer is associated with DNA damage which allows subjects to be stratified for particular therapies including immune therapies which may be combined with DNA damage therapeutics. A method for predicting responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint comprises determining the expression level of at least one gene selected from Table 2B, 2A or 1 in a sample from the subject. The determined expression level is used to predict responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint.
1. A method of treating breast cancer in a human subject comprising:
(a) obtaining or having obtained a biological sample of the breast cancer from the human subject;
(b) measuring an expression level of CXCL10 in the biological sample;
(c) calculating a test score by multiplying the expression level of CXCL10 by a weight value of 0.023;
(d) comparing the test score to a pre-determined threshold score, wherein the pre-determined threshold score is 0.3681;
(e) determining that the test score is equal to or greater than the pre-determined threshold score; and
(f) treating the human subject with (i) at least one antagonist of an inhibitory immune check point and/or (ii) at least one agonist of a stimulatory immune check point if the test score is greater than the pre-determined threshold score.
2. The method of claim 1 , further comprising: treating the human subject with a DNA damage therapeutic agent in combination with step (f).
3. The method of claim 1 , wherein
the human subject is treated with at least one antagonist of an inhibitory immune check point.
4. The method of claim 3 , further comprising: treating the human subject with a DNA damage therapeutic agent in combination with the at least one antagonist of the inhibitory immune check point.
5. The method of claim 4 , wherein the DNA damage therapeutic agent is chosen from the group consisting of a DNA damaging agent, a DNA repair targeted therapy, an inhibitor of DNA damaging signaling, an inhibitor of DNA damage induced cell cycle arrest, and an inhibitor of a process indirectly leading to DNA damage.
6. The method of claim 3 , wherein the at least one antagonist is chosen from the group consisting of an antibody, an inhibitory nucleic acid molecule, MGA271, ipilimumab, indoximod, NLG919, lirilumab, IMP321, BMS-986016, CT-011, nivolumab/BMS-936558, BMS-936559, MGB453, LAG525, PDR001, and pembrolizumab.
7. The method of claim 3 , wherein the inhibitory immune checkpoint is selected from the group consisting of A2AR, B7-H3 (CD276), B7-H4 (VTCN1), BTLA (CD272), CTLA-4 (CD152), IDO, KIR, LAG3, PD-1/PD-L1, TIM-3, and VISTA.
8. The method of claim 1 , wherein
the human subject is treated with at least one agonist of a stimulatory immune check point.
9. The method of claim 8 , further comprising: treating the human subject with a DNA damage therapeutic agent in combination with the agonist of the inhibitory immune check point.
10. The method of claim 9 , wherein the DNA damage therapeutic agent is chosen from the group consisting of a DNA damaging agent, a DNA repair targeted therapy, an inhibitor of DNA damaging signaling, an inhibitor of DNA damage induced cell cycle arrest, and an inhibitor of a process indirectly leading to DNA damage.
11. The method of claim 8 , wherein the at least one agonist is selected from the group consisting of an antibody, a lipocalin, a cytokine, CDX-1127, NKTR-214, BMS-663513, TRX518, CP-870893, MEDI0562, MEDI6469, and MEDI6383.
12. The method of claim 8 , wherein the stimulatory immune checkpoint is selected from the group consisting of CD27, CD28, CD40, CD122, CD137, OX40, GITR, and ICOS.
13. The method of claim 1 , wherein the at least one antagonist is chosen from the group consisting of an antibody, an inhibitory nucleic acid molecule, MGA271, ipilimumab, indoximod, NLG919, lirilumab, IMP321, BMS-986016, CT-011, nivolumab/BMS-936558, BMS-936559, MGB453, LAG525, PDR001, and pembrolizumab.
14. The method of claim 1 , wherein the inhibitory immune checkpoint is selected from the group consisting of A2AR, B7-H3 (CD276), B7-H4 (VTCN1), BTLA (CD272), CTLA-4 (CD152), IDO, KIR, LAG3, PD-1/PD-L1, TIM-3, and VISTA.
15. The method of claim 1 , wherein the at least one agonist is selected from the group consisting of an antibody, a lipocalin, a cytokine, CDX-1127, NKTR-214, BMS-663513, TRX518, CP-870893, MEDI0562, MEDI6469, and MEDI6383.
16. The method of claim 1 , wherein the stimulatory immune checkpoint is selected from the group consisting of CD27, CD28, CD40, CD122, CD137, OX40, GITR, and ICOS.
17. The method of claim 2 , wherein the DNA damage therapeutic agent is chosen from the group consisting of a DNA damaging agent, a DNA repair targeted therapy, an inhibitor of DNA damaging signaling, an inhibitor of DNA damage induced cell cycle arrest, and an inhibitor of a process indirectly leading to DNA damage.